AZ sells rights to gastro drug Losec to Cheplapharm in $309m...

AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands to Germany’s Cheplapharm Arzneimittel in a deal worth up to $309 mil

Multiple pharmas pull ranitidine stomach drugs amid growing ...

Supplies of the heartburn drug ranitidine have been recalled globally following a cancer scare involving multiple pharma companies, where a carcinogenic impurity is suspected to be present

AZ takes control of Ironwood's IBS drug in China

AstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an irritable bowel syndrome drug in

J&J gets Stelara okay in Europe for ulcerative colitis

Lilly moves Crohn's drug into phase 3, faces safety setback ...

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce

EU regulators slap safety restriction on Pfizer's Xeljanz

European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher dose in some patients with ulcerative colitis because of concerns of incr